Search

Now showing items 1-2 of 2

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Mohd Nafi, SN; Generali, D; Kramer-Marek, G; Gijsen, M; Strina, C; Cappelletti, M; Andreis, D; Haider, S; Li, J-L; Bridges, E; Capala, J; Ioannis, R; Harris, AL; Kong, A (2014-08-15)

The role of HER4 in breast cancer is controversial and its role in relation to trastuzumab resistance remains unclear. We showed that trastuzumab treatment and its acquired resistance induced HER4 upregulation, cleavage ...

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger, K; Generali, D; Kramer-Marek, G; Gijsen, M; Ng, TB; Wong, JH; Strina, C; Cappelletti, M; Andreis, D; Li, J-L; Bridges, E; Turley, H; Leek, R; Roxanis, I; Capala, J; Murphy, G; Harris, AL; Kong, A (2014-08-30)

Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab ...